Mantle cell lymphoma is a type of cancer that appears in the outer layer of the lymph nodes. Although new treatment advances have improved the success rate of this rare form of lymphoma, the long-term prognosis for the disease is still not good, according to the Leukemia and Lymphoma Society.
Mantle cell lymphoma is generally considered low grade, meaning that it progresses slowly; however, the cancer often spreads to the spleen, liver or bone marrow. In such cases, your chances of successfully recovering from the cancer decrease, according to LymphomaInfo.net.
The average survival rate of mantle cell lymphoma is four years, reports the the Leukemia and Lymphoma Society.
Mantle cell lymphoma typically responds well to the initial treatment used for the cancer, and patients usually experience an average of a 20-month period of remission following this initial treatment. Unfortunately, as reported by the Leukemia and Lymphoma Society, the disease usually returns and becomes more difficult to treat.
Types of Treatment
Treatments for mantle cell lymphoma include chemotherapy, stem cell transplants, radioimmunotherapy and protease-inhibiting drugs. Often doctors rely upon consolidated therapy or on using one type of treatment right after another.
The survival rates for mantle cell lymphoma are simply averages. Your individual prognosis depends upon a number of factors, including your general health, your age and the progression of your cancer.